

# Sze Ling Chan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9227074/publications.pdf>

Version: 2024-02-01

22  
papers

321  
citations

840119

11  
h-index

887659

17  
g-index

22  
all docs

22  
docs citations

22  
times ranked

686  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Two-year clinical outcomes following lower limb endovascular revascularisation for chronic limb-threatening ischaemia at a tertiary Asian vascular centre in Singapore. Singapore Medical Journal, 2022, 63, 79-85.  | 0.3 | 12        |
| 2  | Effect of fertility health awareness strategies on fertility knowledge and childbearing in young married couples (FertStart): study protocol for an effectiveness-implementation hybrid type I multicentre three-arm parallel group open-label randomised clinical trial. BMJ Open, 2022, 12, e051710. | 0.8 | 3         |
| 3  | 12-Months Results From the PRESTIGE Study Using Sirolimus Drug-Eluting Balloons in the Treatment of Complex BTK Tibial Atherosclerotic Lesions in CLTI Patients. Cardiovascular Revascularization Medicine, 2022, 43, 143-146.   | 0.3 | 3         |
| 4  | Early results of an Asian prospective multicenter VenaSeal real-world postmarket evaluation to investigate the efficacy and safety of cyanoacrylate endovenous ablation for varicose veins. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2021, 9, 335-345.e2.                          | 0.9 | 14        |
| 5  | Prescription patterns of outpatients and the potential of multiplexed pharmacogenomic testing. British Journal of Clinical Pharmacology, 2021, 87, 886-894.  | 1.1 | 3         |
| 6  | World's First Experience Treating TASC II C and D Tibial Occlusive Disease Using the Solutio SLR Sirolimus-Eluting Balloon: Six-Month Results From the PRESTIGE Study. Journal of Endovascular Therapy, 2021, 28, 555-566.   | 0.8 | 17        |
| 7  | Utility of a novel high pressure non-compliant balloon for tibial atherosclerotic lesions in Asian patients with chronic limb threatening ischaemia. Vasa - European Journal of Vascular Medicine, 2020, 49, 475-482.  | 0.6 | 2         |
| 8  | Use of Paclitaxel Coated Drug Eluting Technology to Improve Central Vein Patency for Haemodialysis Access Circuits: Any Benefit?. Vascular Specialist International, 2020, 36, 21-27.  | 0.2 | 5         |
| 9  | Economic burden of adverse drug reactions and potential for pharmacogenomic testing in Singaporean adults. Pharmacogenomics Journal, 2019, 19, 401-410.  | 0.9 | 15        |
| 10 | Time course and clinical characterization of cisplatin-induced ototoxicity after treatment for nasopharyngeal carcinoma in a South East Asian population. Head and Neck, 2018, 40, 1425-1433.  | 0.9 | 7         |
| 11 | Pharmacogenomics in Asia: a systematic review on current trends and novel discoveries. Pharmacogenomics, 2017, 18, 891-910.  | 0.6 | 15        |
| 12 | Establishing multiple omics baselines for three Southeast Asian populations in the Singapore Integrative Omics Study. Nature Communications, 2017, 8, 653.   | 5.8 | 39        |
| 13 | Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients. PLoS ONE, 2017, 12, e0186200.  | 1.1 | 36        |
| 14 | Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations. Pharmacogenetics and Genomics, 2016, 26, 28-39.  | 0.7 | 21        |
| 15 | Prevalence and characteristics of adverse drug reactions at admission to hospital: a prospective observational study. British Journal of Clinical Pharmacology, 2016, 82, 1636-1646.   | 1.1 | 67        |
| 16 | Progress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicity. Pharmacogenomics, 2015, 16, 1161-1178.  | 0.6 | 25        |
| 17 | ATTITUDES ON WARFARIN PHARMACOGENETIC TESTING IN CHINESE PATIENTS AND PUBLIC. International Journal of Technology Assessment in Health Care, 2014, 30, 113-120.  | 0.2 | 4         |
| 18 | Willingness-to-pay and preferences for warfarin pharmacogenetic testing in Chinese warfarin patients and the Chinese general public. Personalized Medicine, 2013, 10, 127-137.   | 0.8 | 4         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | The population attributable fraction as a measure of the impact of warfarin pharmacogenetic testing. <i>Pharmacogenomics</i> , 2012, 13, 1247-1256.  | 0.6 | 7         |
| 20 | Effects of CYP4F2 and GGCX genetic variants on maintenance warfarin dose in a multiethnic Asian population. <i>Thrombosis and Haemostasis</i> , 2011, 105, 1100-1102.  | 1.8 | 5         |
| 21 | Exon sequencing and association analysis of EPHX1 genetic variants with maintenance warfarin dose in a multiethnic Asian population. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 35-41.                     | 0.7 | 13        |
| 22 | The art and science of achieving zero COVID-19 transmissions in staff at a large community care facility in Singapore using implementation science: a retrospective analysis. <i>F1000Research</i> , 0, 10, 212. | 0.8 | 4         |